Searchable abstracts of presentations at key conferences in endocrinology

ea0031p146 | Growth and development | SFEBES2013

Pre-clinical investigation of therapy for segmental overgrowth caused by constitutive activation of phosphoinositide-3 kinas: lessons for cancer therapy

Parker Victoria , Groeneveld Matthijis , Zhang Qifeng , Rudge Simon , Lindhurst Marjorie , Huson Susan , O'Rahilly Steven , Biesecker Leslie , Barroso Ines , Wakelam Michael , Semple Robert

Introduction: We recently reported cases of segmental overgrowth due to mosaic heterozygous activating mutations in the p110α catalytic subunit of PI3K. The index case presented with life-long, massive overgrowth of both legs with a lean upper body. Mobility was threatened by continued growth. mTORC1 inhibition has been effective at slowing excess growth due to loss of PTEN function, a negative regulator of PI3K. We hypothesised that mTORC1 inhibition would also be effect...

ea0031p187 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2013

Acute effects of co-infusion of peptide YY (3–36) and glucagon-like peptide-1 on insulin secretion and insulin sensitivity

Tan Tricia , Salem Victoria , Troke Rachel , De Silva Akila , Alsafi Ali , Misra Shivani , Baynes Kevin , Ghatei Mohammed , Minnion James , Field Ben , Godsland Ian , Bloom Stephen R

The amelioration of type 2 diabetes and sustained weight loss after bariatric surgery are thought to be due to elevated circulating levels of the gut hormones peptide YY3–36 (PYY3–36) and glucagon-like peptide-1 (GLP-1). GLP-1 augments the insulin response to an oral glucose load. PYY3–36 has appetite-inhibitory effects and contributes to longer-term weight loss. Rodent studies provide conflicting data regarding the effects of PY...

ea0015p186 | Endocrine tumours and neoplasia | SFEBES2008

A succinate dehydrogenase B (SDHB) founder mutation

Hughes Katherine , McDougall Lindsay , Bradshaw Nicola , Perry Colin , Lindsay Robert , McConachie Michelle , Davidson D Fraser , Murday Victoria , Connell John M C

Phaeochromocytomas (PHAEO)/paragangliomas (PGL) are neuro-endocrine tumours. They may present sporadically or as the primary abnormality in a number of familial syndromes. Advances in molecular genetics have led to the identification of several PHAEO/PGL predisposing genes including VHL, NF1 and RET. Mutations in the genes encoding the subunits of Succinate Dehydrogenase (SDH) have also been reported. We describe the phenotype of a cohort of patients with a Succinate Dehydroge...

ea0013oc17 | Novartis Clinical Endocrinology Award | SFEBES2007

Kisspeptin-54 potently stimulates luteinising hormone release during the preovulatory phase of the menstrual cycle in healthy human females.

Chaudhri Owais , Dhillo Waljit , Thompson Emily , Murphy Kevin , Salem Victoria , Patterson Michael , Donaldson Mandy , Amber Vian , Ramachandran Radha , Nijher Gurjinder , Kokkinos Alexander , Ghatei Mohammad , Bloom Steve

Kisspeptin, the endogenous ligand of the GPR54 receptor, is a key regulator of the hypothalamo-pituitary-gonadal (HPG) axis. GPR54-null mice exhibit reproductive dysfunction and exogenous kisspeptin potently stimulates the HPG axis in rodents, primates and human males. The effects of kisspeptin administration to human females are not known.Aim: To investigate the effects of kisspeptin on luteinising hormone (LH) release during the menstrual cycle in fema...

ea0013oc27 | Neuroendocrinology, reproduction and cardiovascular | SFEBES2007

Manganese-enhanced MRI demonstrates that oxyntomodulin and GLP-1 affect neuronal activity in distinct regions of the brain

Chaudhri Owais , Parkinson James , Herlihy Amy , Salem Victoria , Kuo Yu-Ting , Bell Jimmy , So Po-Wah , Dhillo Waljit , Stanley Sarah , Ghatei Mohammad , Bloom Steve

The rise in the prevalence of obesity has imparted urgency to the study of the mechanisms of appetite regulation. Oxyntomodulin (OXM) and glucagon-like peptide-1 (GLP-1) are anorexigenic gut hormones thought to act via the same receptor. There is an increasing body of evidence, however, that they may act via distinct pathways. Magnetic resonance imaging (MRI) is increasingly being used as a tool for tracking changes in neuronal activity in vivo through time. Manganese-e...

ea0056oc10.4 | Cardiovascular aspects of endocrine diseases | ECE2018

Improvement in the control of hypertension in diabetic patients screened for hyperaldosteronism

Jimenez Ines , Crespo Irene , Cuesta Martin , Elvira Carlos , de Miguel Paz , Santiago Alejandro , Fernandez Luzdivina , de Parayuelo Maria Victoria Saez , Calle Alfonso , Runkle Isabelle

Introduction: Control of hypertension (HT) is essential to reduce cardiovascular events in diabetic patients (DPts). However, studies indicate that only 50% of DPts with treated hypertension present adequate blood pressure (BP) control. Yet Endocrine-Society-Guideline (ESG) screening for primary hyperaldosteronism (PHA) is rarely applied. Furthermore, in patients with essential hypertension (EH), longer-acting hypertension medication (HM) improves 24-hour BP when compared to r...

ea0056p199 | Bone ' Osteoporosis | ECE2018

Long term follow up of patients with hypophosphatemic rickets in a Public Institution in Brazil

Vieira Oberger Marques Julia , Cervi Lagana Caio , Frare Junior Neudir , Oliboni Do Amaral Patricia , Besen Debora , Robl Marcela , Zegbi Cochenski Borba Victoria , Aguiar Moreira Carolina

Introduction: Hypophosphatemic rickets comprehends a group of hereditary diseases characterized by hypophosphatemia and defective bone mineralization. The most common form is X-linked, with a prevalence of 1:20.000.Objectives: Describe the follow up of patients with hypophosphatemic rickets in a public center in Brazil.Methods: Patients with hypophosphatemic rickets were selected from a database of Endocrinology and Metabolism Serv...

ea0056p632 | Clinical case reports - Thyroid/Others | ECE2018

Patient with neurofibromatosis type 1 and follicular thyroid cancer

Kanouta Fotini , Kalaitzidou Styliani , Triantafillou Eleni , Drousou Aspasia , Kyrimis Taxiarchis , Tampouratzi Dimitra , Kotis Michalis , Papadakis Georgios , Kaltzidou Victoria , Veniou Eirini , Drakopoulou Anna , Karavasili Chrysa , Mastorakos Georgios , Tertipi Athanasia

Objectives: Neurofibromatosis type 1 (NF1) is an autosomal, dominant, genetic disorder. The genetic lesion in neurofibromatosis type 1 is located at locus 17q11.2 that harbors the neurofibromin gene. Patients have 3-4 times higher possibility to develop malignancies relative to the general population. The endocrine manifestations of neurofibromatosis include precocious puberty, short stature, osteoporosis and pheochromocytoma. We present a patient with neurofibromatosis type 1...

ea0056p754 | Neuroendocrinology | ECE2018

Initiation of tolvaptan therapy for mild/moderate chronic SIADH-induced hyponatremia in a day-ward

Ramos Elvira , Barrio Elvira , Miguel Paz de , Cuesta Martin , Fernandez Luzdivina , Victoria Saez de Parayuelo Maria , Maria Cruz Anba , Ortiz Marta , Calle Alfonso , Runkle Isabelle

Introduction: Tolvaptan is the only V2-receptor antagonist authorized for use in Europe in patients with SIADH. Its initiation requires hospitalization. Our goal was to analyze the safety and efficacy of tolvaptan started in a Hospital Day-Ward.Material and methods: Retrospective descriptive study of 33 ambulatory patients with mild/moderate SIADH-induced chronic sustained hyponatremia initiating tolvaptan therapy in the Day-Ward of a tertiary center ove...